Ellen Baron, Ph.D. has over 20 years of operating and investment expertise in the pharmaceutical and biotechnology industry and is focused on all areas of healthcare investing with specific focus in oncology, neurology, orthopedics and infectious disease. Prior to joining Oxford Bioscience Partners, Dr. Baron was Senior Vice President of Business Development at Human Genome Sciences, Inc. Prior to Human Genome Sciences, she spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron received a B.A. from Goucher College, Ph.D. in Microbiology from Georgetown University School of Medicine and post-doctorate at the Public Health Research Institute in New York.

Jack Davis is an experienced CEO with 25 years of general management experience in the healthcare industry. Jack was co-founder and CEO of DIANON Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services focused on cancer, prenatal genetics and cytogenetics. DIANON was taken public in 1991 and was sold to Laboratory Corp of America for $600MM in 2003. Jack had previously managed a $100MM worldwide diagnostic products business for Abbott Laboratories. He currently serves as Director of several med-tech companies. Jack holds a B.S. from Ohio State University, completed the Exec Development Program at Ohio State and served as an Adjunct Professor of Business at Sacred Heart University.

Marc Goldberg co-founded BioVentures Investors where he is a General Partner. He has over twenty years of experience in the biotechnology industry as both senior executive and deal maker. From 1991 to 1997 Mr. Goldberg was President and CEO of Massachusetts Biotechnology Research Institute (Worcester, Massachusetts). He was responsible for the financing, strategic direction, and operation of this private sector economic development organization which specialized in technology transfer and company formation. During his tenure, MBRI raised $20 million in funding and was responsible for the launch of 24 new biotechnology companies. MBRI's success served as a model for the development of similar systems throughout the U.S. as well as internationally. From 1987 to 1991, Mr. Goldberg held senior positions at Safer, Inc. (Newton, Massachusetts), including Chief Financial Officer and Vice President, Finance and Corporate Development. He negotiated four rounds of venture capital investment, numerous bank lines of credits, and multiple manufacturing contracts. He implemented all outside scientific collaborations with both public and private entities, handled the sale of Safer’s consumer division, managed the company between CEOs, positioned the company for sale, and negotiated the final merger agreement. Prior to Safer, Mr. Goldberg was Manager of Business Development at Genetics Institute, Inc. (Cambridge, Massachusetts) from 1983 to 1987. He was responsible for the company’s agricultural business development, strategic planning, and marketing functions. Mr. Goldberg co-founded the Massachusetts Biotechnology Council in 1985, and has served four terms as President and was a Director from its inception in 1985 until 1997. He has also served as a board member of numerous privately held companies. He was a member and principal author of the Governor’s Task Force, Subcommittee on Biotechnology and Pharmaceutical Development. He was a Governor of the Harvard Business School Association of Boston and was Chairman of the Board of Trustees at Worcester State College. Mr. Goldberg earned his A.B. from Harvard College (Phi Beta Kappa, magna cum laude), his J.D. from Harvard Law School (cum laude), and his M.B.A. from Harvard Business School.

Michael J. Magliochetti, Ph.D. was previously an Entrepreneur-in-Residence at Oxford Bioscience Partners. He was most recently CEO of RMH, a company focused in orthopedics, which was acquired. He was CEO of HemaMetrics, a private blood monitoring and diagnostic company. Dr. Magliochetti was CEO of UroSurge, specializing in products for the urology market of which a sale transaction was executed. He has held senior positions with the medical device company Haemonetics Corporation and the polymer products company Delta Surprenant. He currently serves on the Advisory Board for the Pediatric New Technology Initiatives Group of Boston Children's Hospital, the non-profit Institute for Pediatric Innovation, and has served as an Adjunct Professor of Biomedical Engineering at the University of Iowa. Dr. Magliochetti holds B.S. and Ph.D. degrees in Chemical Engineering from Northeastern University and the University of Massachusetts at Amherst, respectively, and a High Technology M.B.A. from Northeastern University.

Caroline Popper, M.D. is Founder and President of Popper & Co., a life sciences consulting firm. She has 17 years of biotech/life sciences operating experience managing businesses in diagnostics, devices and drug discovery in both Fortune 500 and start-up settings. Dr. Popper has extensive diagnostic industry experience with the majority of her career at Becton Dickinson, where her global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding GM of BDGene; a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Dr. Popper has served as Chief Business Officer for MDS Proteomics, a multi-national drug discovery company. Dr. Popper received her MD from the University of the Witwatersrand (South Africa), completed her residencies in Internal Medicine and in Pathology at Johns Hopkins, and attained a MPH from Johns Hopkins University. She was also a Robert Wood Johnson Fellow in Health Care Finance.

David Steinmiller previously served as Director of Engineering at WebOligos and Eos Biotechnology where he developed instruments for genomics research. Mr. Steinmiller created and patented a high-throughput system for synthesizing nucleic acids and transitioned the technology from concept to prototype to production device. This technology formed the core of WebOligos, which produced and marketed synthetic DNA, and which was acquired by Invitrogen. Mr. Steinmiller holds a B.S. and M.S. in Mechanical Engineering from Stanford and an MBA from the MIT Sloan School of Management.